Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Federica Di Nicolantonio

Showing results (1-10 of 132) with videos related to

Pageof 14
Sort By:
Methods in Molecular Biology (Clifton, N.J.)|April 26, 2011
Transfection and DNA-mediated gene transferDavide Zecchin, Federica Di Nicolantonio
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 25, 2013
Mouse models of Kras-mutant colorectal cancer: valuable GEMMs for drug testing?Federica Di Nicolantonio, Alberto Bardelli
Current Opinion in Oncology|December 17, 2005
Kinase mutations in cancer: chinks in the enemy's armour?Federica Di Nicolantonio, Alberto Bardelli
Cancer Discovery|January 10, 2014
Climbing RAS, the everest of oncogenesMariangela Russo, Federica Di Nicolantonio, Alberto Bardelli
Nature Reviews. Clinical Oncology|July 10, 2013
Liquid biopsy: monitoring cancer-genetics in the bloodEmily Crowley, Federica Di Nicolantonio, Fotios Loupakis, et al.
Molecular Oncology|February 5, 2019
Exploiting DNA repair defects in colorectal cancerNicole M Reilly, Luca Novara, Federica Di Nicolantonio, et al.
Cancer Discovery|October 9, 2014
Resistance to anti-EGFR therapy in colorectal cancer: from heterogeneity to convergent evolutionSandra Misale, Federica Di Nicolantonio, Andrea Sartore-Bianchi, et al.
Journal of the National Cancer Institute|September 10, 2009
Biomarkers predicting clinical outcome of epidermal growth factor receptor-targeted therapy in metastatic colorectal cancerSalvatore Siena, Andrea Sartore-Bianchi, Federica Di Nicolantonio, et al.
Current Opinion in Investigational Drugs (London, England : 2000)|July 2, 2002
Chemosensitization of solid tumor cells by alteration of their susceptibility to apoptosisIan A Cree, Louise Knight, Federica Di Nicolantonio, et al.
Human Mutation|November 28, 2013
Targeted knock-in of the polymorphism rs61764370 does not affect KRAS expression but reduces let-7 levelsEmily Hannah Crowley, Sabrina Arena, Simona Lamba, et al.
Pageof 14

Showing results (1-10 of 132) with videos related to

Sort By:
Pageof 14
Methods in Molecular Biology (Clifton, N.J.)|April 26, 2011
Transfection and DNA-mediated gene transferDavide Zecchin, Federica Di Nicolantonio
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 25, 2013
Mouse models of Kras-mutant colorectal cancer: valuable GEMMs for drug testing?Federica Di Nicolantonio, Alberto Bardelli
Current Opinion in Oncology|December 17, 2005
Kinase mutations in cancer: chinks in the enemy's armour?Federica Di Nicolantonio, Alberto Bardelli
Cancer Discovery|January 10, 2014
Climbing RAS, the everest of oncogenesMariangela Russo, Federica Di Nicolantonio, Alberto Bardelli
Nature Reviews. Clinical Oncology|July 10, 2013
Liquid biopsy: monitoring cancer-genetics in the bloodEmily Crowley, Federica Di Nicolantonio, Fotios Loupakis, et al.
Molecular Oncology|February 5, 2019
Exploiting DNA repair defects in colorectal cancerNicole M Reilly, Luca Novara, Federica Di Nicolantonio, et al.
Cancer Discovery|October 9, 2014
Resistance to anti-EGFR therapy in colorectal cancer: from heterogeneity to convergent evolutionSandra Misale, Federica Di Nicolantonio, Andrea Sartore-Bianchi, et al.
Journal of the National Cancer Institute|September 10, 2009
Biomarkers predicting clinical outcome of epidermal growth factor receptor-targeted therapy in metastatic colorectal cancerSalvatore Siena, Andrea Sartore-Bianchi, Federica Di Nicolantonio, et al.
Current Opinion in Investigational Drugs (London, England : 2000)|July 2, 2002
Chemosensitization of solid tumor cells by alteration of their susceptibility to apoptosisIan A Cree, Louise Knight, Federica Di Nicolantonio, et al.
Human Mutation|November 28, 2013
Targeted knock-in of the polymorphism rs61764370 does not affect KRAS expression but reduces let-7 levelsEmily Hannah Crowley, Sabrina Arena, Simona Lamba, et al.
Pageof 14